Earnings season continues to move rapidly, with many companies unveiling quarterly results daily. So far, the period has been positive, though it’s worth noting that estimates for the current period (Q2) have fallen in recent weeks. But throughout the Q1 cycle so far, several companies deeply involved in the AI frenzy – Palantir PLTR and Tempus AI TEM – posted results that had investors pleased, with each seeing bullish post-earnings reactions. Let’s take a closer look at each report. PLTR Again Posts Stellar Results Palantir continued to fire on all cylinders throughout its latest period, with the company again experiencing serious growth. Sales shot 39% higher year-over-year, with the company also raising its current year sales outlook in a big way. As shown below, the company’s sales growth has been outstanding over recent periods, a reflection of the red-hot demand PLTR has been enjoying.Zacks Investment Research Image Source: Zacks Investment Research Notably, customer count grew nearly 40% year-over-year and 8% sequentially. Palantir also booked its highest U.S. commercial total contract value throughout the period ($810 million), which grew a staggering 180% year-over-year. The favorable U.S. contract performance helped drive the 55% year-over-year climb in its U.S. revenue, with U.S. commercial and government revenue improving by 71% and 45% year-over-year, respectively. Analysts have already revised their current year sales expectations for the stock following the release, with the current $3.9 billion Zacks Consensus estimate up nearly 20% over the last year. The company’s sales are now forecasted to climb 37% following the updated guidance, continuing its growth trajectory nicely.Zacks Investment Research Image Source: Zacks Investment Research Tempus AI Sales Surge Higher Tempus AI is a technology company leading the adoption of AI to advance precision medicine and patient care. Like PLTR, the company enjoyed serious growth, with sales of $255.7 million climbing 75% year-over-year. Below is a chart illustrating the company’s sales on a quarterly basis.Zacks Investment Research Image Source: Zacks Investment Research Margin improvement also led to notable benefits, with quarterly gross profit of $155.2 million doubling from the year-ago period. Adding to the positivity, the company also announced multi-year collaborations with AstraZeneca and Pathos, which are expected to result in roughly $200 million in data licensing and model development fees over the next three years. Notably, its Genomics segment saw its sales grow 90% year-over-year, with its Data and services revenue of $61.9 million up 43.2% from the same period last year. And to top off the robust results, the company increased its FY25 revenue guidance to roughly $1.3 billion, reflecting a massive 80% growth rate year-over-year. Story Continues Shares saw a nice boost post-earnings, with TEM shares up nearly 50% overall just over the past month.Zacks Investment Research Image Source: Zacks Investment Research Bottom Line We continue to wade through the 2025 Q1 cycle, which has overall been positive. Growth has been strong, though it’s critical to note that tariff concerns have caused downward pressure on earnings estimates for the current (Q2) and coming periods. Still, several AI-related stocks have posted robust results throughout the period, a list that includes Palantir PLTR and Tempus AI TEM. Given these results, both stocks reflect great opportunities to ride the artificial intelligence frenzy, a theme that’s likely just in its early innings. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Palantir Technologies Inc. (PLTR):Free Stock Analysis Report Tempus AI, Inc. (TEM):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
These AI Stocks Posted Robust Results: Time to Buy?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...